Canaccord raised the firm’s price target on Grail (GRAL) to $43 from $32 and keeps a Buy rating on the shares. The firm updated its model following results and said they remain bullish after a solid 1Q25 update, as they think the company will benefit from upcoming catalysts and its “trailblazer” advantage in multi-cancer early detection (MCED).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue